These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
225 related items for PubMed ID: 29719377
1. Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells. Zeng Y, Tian X, Wang Q, He W, Fan J, Gou X. Drug Des Devel Ther; 2018; 12():911-920. PubMed ID: 29719377 [Abstract] [Full Text] [Related]
2. Protective Autophagy Attenuates the Cytotoxicity of MTI-31 in Renal Cancer Cells by Activating the ERK Pathway. Zang Y, Yang C, Dai MS, Zhang W, Zou L, Hu J, Hu Y, Xu C, Liu R, Wang H, Xiong Z. Appl Biochem Biotechnol; 2024 Apr; 196(4):2233-2245. PubMed ID: 37493819 [Abstract] [Full Text] [Related]
3. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells. Lin JF, Lin YC, Yang SC, Tsai TF, Chen HE, Chou KY, Hwang TI. Drug Des Devel Ther; 2016 Apr; 10():1501-13. PubMed ID: 27143856 [Abstract] [Full Text] [Related]
4. The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway. Ji D, Zhang Z, Cheng L, Chang J, Wang S, Zheng B, Zheng R, Sun Z, Wang C, Zhang Z, Liu R, Zhang X, Liu X, Wang X, Li J. PLoS One; 2014 Apr; 9(1):e85116. PubMed ID: 24416349 [Abstract] [Full Text] [Related]
5. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells. Cai Y, Xia Q, Su Q, Luo R, Sun Y, Shi Y, Jiang W. Int J Mol Med; 2013 Apr; 31(4):904-12. PubMed ID: 23426850 [Abstract] [Full Text] [Related]
6. β-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/ mTOR signalling pathways. Zhan YH, Liu J, Qu XJ, Hou KZ, Wang KF, Liu YP, Wu B. Asian Pac J Cancer Prev; 2012 Apr; 13(6):2739-44. PubMed ID: 22938451 [Abstract] [Full Text] [Related]
7. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J. Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441 [Abstract] [Full Text] [Related]
8. Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. Grimaldi A, Santini D, Zappavigna S, Lombardi A, Misso G, Boccellino M, Desiderio V, Vitiello PP, Di Lorenzo G, Zoccoli A, Pantano F, Caraglia M. Cancer Biol Ther; 2015 May; 16(4):567-79. PubMed ID: 25866016 [Abstract] [Full Text] [Related]
9. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent. Xiong Z, Zang Y, Zhong S, Zou L, Wu Y, Liu S, Fang Z, Shen Z, Ding Q, Chen S. Oncotarget; 2017 May 02; 8(18):30151-30161. PubMed ID: 28404914 [Abstract] [Full Text] [Related]
10. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells. Avniel-Polak S, Leibowitz G, Riahi Y, Glaser B, Gross DJ, Grozinsky-Glasberg S. Neuroendocrinology; 2016 May 02; 103(6):724-37. PubMed ID: 26619207 [Abstract] [Full Text] [Related]
11. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH, He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, Yang T, Chen XW, Qiu JX, Zhou SF. Drug Des Devel Ther; 2015 May 02; 9():1555-84. PubMed ID: 25792811 [Abstract] [Full Text] [Related]
12. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Ou YC, Yang CR, Cheng CL, Raung SL, Hung YY, Chen CJ. Eur J Pharmacol; 2007 Jun 01; 563(1-3):49-60. PubMed ID: 17341418 [Abstract] [Full Text] [Related]
13. Fisetin Suppresses the Proliferation and Metastasis of Renal Cell Carcinoma through Upregulation of MEK/ERK-Targeting CTSS and ADAM9. Hsieh MH, Tsai JP, Yang SF, Chiou HL, Lin CL, Hsieh YH, Chang HR. Cells; 2019 Aug 21; 8(9):. PubMed ID: 31438640 [Abstract] [Full Text] [Related]
15. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. Juengel E, Engler J, Natsheh I, Jones J, Mickuckyte A, Hudak L, Jonas D, Blaheta RA. BMC Cancer; 2009 May 27; 9():161. PubMed ID: 19473483 [Abstract] [Full Text] [Related]
17. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma. Zheng B, Mao JH, Qian L, Zhu H, Gu DH, Pan XD, Yi F, Ji DM. Cancer Lett; 2015 Feb 28; 357(2):468-75. PubMed ID: 25444920 [Abstract] [Full Text] [Related]
19. Bisebromoamide, an extract from Lyngbya species, induces apoptosis through ERK and mTOR inhibitions in renal cancer cells. Suzuki K, Mizuno R, Suenaga K, Teruya T, Tanaka N, Kosaka T, Oya M. Cancer Med; 2013 Feb 28; 2(1):32-9. PubMed ID: 24133625 [Abstract] [Full Text] [Related]
20. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways. Liu QJ, Shen HL, Lin J, Xu XH, Ji ZG, Han X, Shang DH, Yang PQ. Drug Des Devel Ther; 2016 Feb 28; 10():745-55. PubMed ID: 26937175 [Abstract] [Full Text] [Related] Page: [Next] [New Search]